OR WAIT null SECS
May 15, 2025
Article
Recent data from the GALE trial align with OAKS and DERBY results, indicating a successful treatment of geographic atrophy.
May 14, 2025
Video
Goldberg’s post hoc analysis has indicated that AREDS and AREDS2 vitamins do not slow either GA progression to the fovea or overall GA growth.
May 10, 2025
Stay updated with the latest healthcare breakthroughs, including cholesterol treatments and innovative therapies for AMD and psoriasis, in this week's roundup.
May 09, 2025
The recent trial indicates that the oral treatment gildeuretinol reduces GA lesion growth rates, as well as achieving better BCVA scores.
May 08, 2025
Data released by Cognition Therapeutics shows that oral zervimesine resulted in substantially reduced lesion growth over 18 months compared to placebo.
A post hoc analysis of trial data reveals the effects of intraretinal fluid on best-corrected visual acuity in patients after port delivery system treatment for nAMD.
April 26, 2025
Gene therapy could revolutionize retinal disease treatment, promising consistent dosing, fewer injections, and improved patient outcomes, as highlighted by expert Christina Y. Weng.
April 16, 2025
The study indicates which biomarkers should be prioritized to predict neovascular AMD and geographic atrophy.
April 10, 2025
Tailor discusses the future of AI in ophthalmology and beyond, and some of the challenges it may bring.
April 08, 2025
Our Q1 2025 recap for ophthalmology spotlights 5 regulatory updates, 5 key trial announcements, and two episodes of our flagship ophthalmology podcast.
